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Abstract
Background and Aims—Growing evidence demonstrates adverse effects of narcotics in
inflammatory bowel disease (IBD). We sought to study the relationship between narcotic use,
objective measures of disease activity and other associated factors in hospitalized patients with
IBD.
Methods—We performed a retrospective cohort study of all adult IBD patients admitted to a
general medical or surgical ward service at a United States tertiary care center over a 1 year
period. We collected demographic and disease specific information, inpatient narcotic use and
disease activity measurements from endoscopic and radiologic reports. Bivariate comparisons
were made between characteristics and narcotic use. Logistic regression was used to evaluate the
independent effects of characteristics on narcotic use.
Results—A total of 117 IBD patients were included. Narcotics were given to 70.1% of
hospitalized patients. Factors significantly associated with any inpatient narcotic use: Crohn’s
disease (CD); p=<0.01, duration of IBD, p=0.02, prior psychiatric diagnosis, p=0.02, outpatient
narcotic use, p=<0.01, current smoking, p=<0.01, prior IBD-specific surgery, p<0.02, and prior
IBD-IBS diagnosis, p=0.02. Narcotic use was not significantly associated with disease severity on
computed tomography (CT) scan or endoscopy. On multivariate analysis, smoking (OR 4.34, 95%
CI 1.21–15.6) and prior outpatient narcotic use (OR 5.41, 95% CI 1.54–19.0) were independently
associated with inpatient narcotic use.
Conclusions—A majority of patients with IBD are prescribed narcotics during hospitalization in
spite of data on increased complications. Risk factors for narcotic use include CD and associated
factors (disease duration, surgeries), substance abuse (outpatient narcotics and smoking),
psychiatric diagnoses and IBD-IBS.
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Many patients with inflammatory bowel disease (IBD) suffer from chronic abdominal pain.
The perception of pain in those with IBD can vary significantly. As many as 20% of patients
with resolving inflammation and clinical remission can still have chronic pain.1 In the past
narcotics were often contraindicated in patients with IBD for fear of precipitating toxic
megacolon. Now, narcotics are increasingly prescribed for chronic pain in non-malignant
disease, and thus are commonly used in the IBD population. The United States is estimated
to use 80% of the world’s opioids, in spite of only representing 4.6% of the world’s
population.2 For example, retail sales of opioids have skyrocketed in the past decade;
prescriptions for methadone have increased 1177% from 1997–2006.3 It is estimated that
approximately 5–13% of patients with IBD are on chronic narcotics in the outpatient
setting. 4, 5 Similarly, in patients with irritable bowel syndrome (IBS), national surveys have
estimated that 8% of the population are on chronic narcotics.6
Several factors have been associated with outpatient narcotic use in the IBD population.
These factors include psychiatric comorbidities such as depression and anxiety, a history of
abuse, female gender, and clinical disease activity when measured by symptoms.4, 5, 7 Cross
et al used the Harvey-Bradshaw Index to assess disease activity, which includes
measurements of general well-being and abdominal pain, which may not necessarily be
associated with active inflammation.5 Many of the symptoms in scales of IBD disease
activity are also symptoms of IBD-irritable bowel syndrome (IBD-IBS).2 Irritable bowel
syndrome (IBS) can coexist with IBD, as can chronic widespread pain.8 The prevalence of
IBS symptoms in patients with IBD is estimated to be 2–3 times higher than that of the
general population. Approximately 57% of patients with Crohns disease (CD) and 33% of
patients with ulcerative colitis (UC) report IBS-like symptoms.9 IBD-IBS is defined by
disproportionate degrees of pain and diarrhea relative to the observed disease activity.10 The
overlap of IBD-IBS may be partially responsible for chronic abdominal pain in IBD and
may be a risk factor for narcotic use.
Little is known about narcotic use in patients hospitalized with IBD. One recent study of the
association between narcotic use and colectomy in UC found that only 19.7% of patients
required narcotic analgesics prior to colectomy.11 Because narcotics have been associated
with complications of IBD and are also associated with significant mortality12, rates of
narcotic use in both UC and CD and risk factors for use during hospitalization need to be
quantified. We therefore sought to quantify narcotic use in patients hospitalized for a
primary indication of IBD at a single tertiary care center. We also aimed to describe the
relationship between narcotic use, objective measures of disease activity and other
associated factors, including prior diagnosis of IBD- IBS, in hospitalized patients with IBD.
Methods
Study Design
We performed a retrospective cohort study of all patients ≥ 18 years old admitted to the
University of North Carolina at Chapel Hill from May 1, 2008–April 30, 2009 for a primary
indication of IBD and seen by the adult gastroenterology consultation service. At our
institution, patients with IBD are admitted to an adult general medical ward service or a
specialized gastrointestinal surgery service, with consultation by the medical
gastroenterology service. Primary medication prescriptions are provided by the ward
services. As a different system of practice is in place for pediatric patients at our institution,
these patients were excluded from the study. Each unique patient was only included in the
study for their first hospitalization over the study period. Information on narcotic use,
demographic and clinical information was abstracted from the electronic medical record. For
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any patient who ultimately underwent surgery during his or her admission, data were
censored at the time of surgery.
Patient selection
All patients ≥ 18 years old, whose initial consultation for IBD was not within 1 month post
operation for IBD, and who did not have an intra-abdominal abscess during the studied
admission were included in the study population. Post-operative and intra-abdominal
abscess patients were excluded related to specific increased narcotic requirements for pain
control in these conditions.
Assessment of Exposures
Demographic information including age, gender, tobacco and alcohol use, marital status (as
a measure of social support) and health insurance status were abstracted from the medical
record. Disease characteristics including type of IBD (CD versus UC), duration of IBD,
prior IBD-specific surgeries, presence of active perianal disease, a prior diagnosis of IBD-
IBS, presence of a stricture on computed tomography (CT) scan or colonoscopy during this
admission, whether a surgery was performed during the admission, and hospital length of
stay were also collected. IBD-IBS was defined as disproportionate degrees of pain and
diarrhea relative to the observed disease activity and had to be diagnosed by a physician
prior to the admission.10 Additionally, we recorded whether patients had a prior psychiatric
diagnosis, defined as depression or anxiety disorder, and whether they were on psychiatric
medications prior to admission. Psychiatric medications included any tricyclic
antidepressant, selective serotonin reuptake inhibitor (SSRI), selective norepinephrine
reuptake inhibitor (SNRI), antipsychotic, atypical antipsychotic, or benzodiazepine class of
medication. Body mass index (BMI) was also abstracted when available. If a patient went to
surgery during the admission, all data, including hospital length of stay, were censored at the
time of surgery.
Assessment of Disease Severity
Disease severity was measured for endoscopic (colonoscopy, ileoscopy or pouch exam) and
radiologic (CT scan) tests performed in the one week prior to or during admission by 2
separate gastroenterologists (ML and HH). The physicians were blinded to narcotic
requirements and other clinical characteristics during the hospitalization. Endoscopic
findings were defined as normal, mild, moderate or severe based on endoscopic reports,
photographs and pathology results. Findings on CT scan were classified as normal (no
abnormal bowel or intra-abdominal findings), mild/moderate (thickening of bowel wall
only) or severe (thickening of bowel wall with evidence of extraluminal inflammatory
changes or dilation of bowel). A stricture on endoscopic or radiologic test was classified
separately. Endoscopic severity was then categorized as low (normal or mild) or high
(moderate or severe). In order to be placed in the high category, both reviewers had to score
the findings as at least moderate. Radiologic severity was categorized as low (normal or
mild/moderate) or high (severe). In order to be placed in the high category, both reviewers
had to score the findings as severe.
Assessment of Outcome (Narcotic Use)
Many narcotic orders for inpatients are written in an as needed format. Because of this, we
used billing records rather than medical orders to determine narcotics received during
hospitalization. Any billing record for a narcotic analgesic (see Appendix 1 for complete
list) and the date and time of delivery for each study patient were electronically retrieved.
Those medications given for conscious sedation for a procedure were excluded (most often
fentanyl). Any patient who underwent surgery during the admission was censored at the
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time of surgery, so that post-operative pain management was not included in the assessment
of narcotic use. All narcotics were converted to intravenous (IV) morphine equivalents using
Med Calc®.13 As there is no direct conversion for transdermal fentanyl patch, conversion
was performed via the method of Donner, with a conversion rate of oral morphine to
transdermal fentanyl of 100:1. This conversion method has been validated in a population of
patients with malignant pain.14 For those patients requiring a patient controlled analgesia
(PCA) pump, billing records were only able to provide the total amount of narcotics placed
in the pump, therefore actual delivered dosing for these patients could not be obtained. Total
narcotic use was reported as average milligram (mg) per day (total IV morphine
requirements/total hospital length of stay). Peak narcotic use was defined as highest mg of
IV morphine equivalents required over a 24 hour period. Narcotic use was also classified
into a dichotomous variable (any/none). This variable was used in all analyses, as we were
able to definitively determine whether narcotics were given from billing records.
Statistical Analysis
Bivariate comparisons were made between exposures, disease severity measurements and
categories of narcotic use (any/none), using Pearson’s chi squared test statistic or Wilcoxon
rank sum test as appropriate. For assessment of disease severity via radiologic or endoscopic
reports, only those obtaining the test during the hospitalization were included in analyses.
Logistic regression modeling was used to determine risk factors independently associated
with narcotic use. Candidate variables for the model were selected a priori from the
literature. For all analyses, a p value of 0.05 (2-sided) was considered statistically
significant. Stata 11.0 (College Station, TX) was used for all analyses. The Institutional
Review Board at the University of North Carolina at Chapel Hill approved the study
protocol.
Results
A total of 144 consultations in unique patients for an indication of IBD occurred over the 1
year study period from May 1, 2008–April 30, 2009. A total of 5 patients were excluded due
to an IBD specific surgery < 1 month prior to hospitalization, 1 was excluded due to ultimate
diagnosis of combined variable immunodeficiency rather than IBD, 21 were excluded
related to an intra-abdominal abscess at the time of hospitalization, leaving 118 unique
patients with IBD in the study population (Figure 1). The majority of the population had CD
(71.8%). For both CD and UC, the majority of those hospitalized were female. Nearly ¼ of
those with CD had a prior psychiatric diagnosis, and >1/3 were on a psychiatric medication.
A total of 48.6% of patients on a psychiatric medication prior to admission did not have a
prior psychiatric diagnosis. In this group, benzodiazepines were the most commonly
prescribed agent. Additionally, >1/3 of patients with CD were current smokers, in spite of
evidence that smoking may exacerbate underlying CD. Characteristics of the population by
CD or UC status are shown in Table 1. Patients with CD had significantly longer disease
duration, were older, had more prior surgeries, perianal disease and strictures. CD patients
also had significantly more psychiatric medications and less evidence of endoscopic disease
severity.
A total of 70.1% of patients with IBD received narcotics for pain control during their
admission. Among those patients who did receive narcotics in an as needed or scheduled
format, the median peak (over 24 hours) narcotic use in intravenous (IV)morphine
equivalents was 12 mg, interquartile range (IQR) 6–20 mg. The median daily average
narcotic use (total amount averaged over total # of days of hospitalization) was 7.5 mg/day,
IQR 2.5–12.7 mg/day. In addition, a total of 7.7% of the population required a patient
controlled analgesia (PCA) pump during hospitalization. Billing records for those using
PCAs could not provide the delivered narcotic dose; these records only reported the total in
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the pump. Because of this, narcotic amounts for those on PCAs were not included in peak or
average daily narcotics calculations. These calculations therefore represent an
underestimation of actual narcotics given during hospitalization for IBD.
Characteristics of the population by any narcotic use are shown in Table 2. Several features
were significantly associated with any narcotic use during hospitalization. These factors
included: Crohn’s disease, duration of IBD, prior psychiatric diagnosis, outpatient narcotic
use, current smoking, prior IBD-specific surgery and prior diagnosis of IBD-IBS.
Interestingly, requirement for surgery during the hospitalization was not significantly
associated with narcotic use. When the IBD-IBS population was compared to the IBD
population, 100% versus 67% required narcotics during admission (p=0.02). Disease
severity as assessed by endoscopic or radiologic criteria was not significantly associated
with narcotic use.
A total of 45.3% (n=53) of patients were discharged from the hospital with a prescription for
a narcotic pain medication. A quarter (24.5%, n=13) of these patients underwent a surgery
during the hospitalization. Factors significantly associated with narcotics prescribed at
discharge included: chronic outpatient narcotics prior to admission, receipt of narcotics
during hospitalization, surgery during the admission and perianal disease (data not shown).
Multivariate logistic regression was used to evaluate the independent effects of factors
associated with narcotic use during hospitalization. Prior substance abuse, either via
smoking (OR 4.34, 95% CI 1.21–15.6) or outpatient narcotic use (OR 5.41, 95% CI 1.54–
19.0), was independently associated with narcotic use during hospitalization. While not
significant, prior psychiatric diagnoses were also associated with narcotic use (2.15, 95% CI
0.40–11.6) (table 3).
Discussion
This referral based retrospective cohort study demonstrates that a majority of patients with
IBD (>70%) received narcotics during hospitalization. Even though calculated daily average
doses of morphine likely represent an underestimation due to the inability to capture data
from PCA pumps, a significant daily dose was still received. Not only are IBD patients
receiving narcotics, they are receiving substantial doses over the course of hospitalization
for pain control. Thus, it is important to understand what kinds of factors affect narcotic
prescribing for IBD; as narcotics may be a risk factor for increased infectious complications
and even increased mortality.12 In this study, were able to quantify narcotic use, and also
describe risk factors present on admission for receipt of narcotics during the hospitalization.
These risk factors include psychiatric diagnoses, smoking, prior outpatient narcotic use,
IBD-IBS, CD rather than UC and prior IBD-related surgery. Most of these risk factors are
independent of IBD diagnosis and disease activity. When we compared narcotic use by
objective measures of disease activity, we did not find a significant association. Therefore,
the most severe disease activity findings do not necessarily correlate with narcotic
requirements. In fact, all patients with a prior diagnosis of IBD-IBS, defined as painful
symptoms in the absence of disease activity, received narcotics during hospitalization.
Interestingly, in the overall hospitalized IBD population 61.5% were female, which differs
from the known equal incidence of IBD among men and women. IBS is more prevalent
among women. When we excluded the IBD-IBS group, 57.6% of the population was female.
Therefore, IBD-IBS is the likely cause of the gender disproportion. When we investigated
factors associated with narcotics at discharge, factors such as prior narcotic use and surgery
were significant predictors. Interestingly, perianal disease was associated with discharge
narcotic prescriptions. This may be related to the fact that this is an external manifestation of
IBD that can be visualized by the treating physician, and is recognized as a “valid” source of
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pain amenable to such treatment. By recognition of risk factors for narcotic use, alternative
pain control therapies could be implemented earlier in the course of hospitalization. Pain is
not necessarily a marker of intestinal inflammation, but can by itself represent an illness
symptom.15 Severe inflammatory activity can be painless. Thus, the treatment approach to
pain in IBD should include balanced therapies targeting the brain and the gut.
Narcotics can have adverse complications in patients with chronic gastrointestinal
conditions, such as IBD. Opioids can be associated with reduced gastrointestinal motility,
nausea, vomiting, constipation, secondary intestinal pseudo-obstruction, and
gastroparesis.2, 16 Pain control in patients with IBD can be difficult, as other traditional
agents for pain control such as non steroidal anti-inflammatory drugs (NSAIDS) have been
associated with flares of IBD in epidemiologic studies.17 For this reason, there may be a role
for antidepressants and psychological support in pain management in IBD. The central
analgesic effects of antidepressant medications can be beneficial. This under-recognized
mechanism of pain control is often used in patients with functional gastrointestinal
disorders, often in combination with psychological interventions. These treatments have
overarching effects on pain regulation, regardless of the source of pain. Patients with IBD on
narcotics are also at risk for development of narcotic bowel syndrome (NBS). NBS is
defined by chronic or recurrent abdominal pain that worsens with continued or escalating
dosages of narcotics.2 In our study sample, a total of 6 IBD patients (5.1%) were diagnosed
with NBS during hospital admission and required a detoxification protocol. This entity is
important to recognize, as increasing doses of narcotics will actually cause or aggravate the
pain that is being treated. Instead, medications such as tricyclic antidepressants or SNRI
antidepressants can be used as centrally acting agents to treat the pain.2
In 2001, the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO)
introduced the concept that pain was the “fifth vital sign.” The purpose was to increase the
awareness and therapy of pain in the hospitalized patient.3 However, this may have resulted
in the overmedication of a group of patients3, 18 and may have additionally influenced
opioid prescribing patterns in patients with IBD. When notified regularly of elevated pain
scores, hospital physicians and trainees may be more inclined to prescribe as needed
narcotics. Additionally, there are national trends influencing narcotic prescriptions in both
the ambulatory and hospital settings. Since the mid 1990’s, physicians have been
encouraged to become more active in identifying and treating chronic pain. Since 1990,
opiod use has increased by a factor of 10.19 Aggressive marketing of controlled release
opiod pain medications has contributed to this phenomenon. As an unintended consequence,
there has been a marked increase in deaths from unintended drug overdoses. 19 This
prescribing pattern may represent a generational change, where younger physicians are
being trained in a climate where narcotic use abounds. Narcotic use is therefore accepted as
a normal component of both the inpatient and outpatient practice of medicine. In this
increasing climate of narcotic use and abuse throughout the United States, it is not surprising
that narcotic use is so common among hospitalized patients with IBD.
In our sample, prior psychiatric diagnosis was associated with narcotic use on bivariate
analysis, and presumably increased pain. Psychological distress and poor coping can act via
central nervous system pathways to produce central disinhibition of incoming visceral
signals, thus amplifying the pain experience and exacerbating other gastrointestinal
symptoms.10, 20 Furthermore, stress and other psychosocial factors can increase pain for all
medical conditions including IBD.21 Walker et al have previously shown that IBD patients
with psychiatric disorders have increased gastrointestinal and other medically unexplained
symptoms despite no differences in severity of IBD.22 Additionally, Guthrie et al showed
that concurrent psychological disorders in patients with IBD contribute to poor health-
related quality of life, independent of IBD disease severity.23 Drossman reported that
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psychological distress and poor general well being lead to increased physician visits in
patients with IBD.24 Therefore, psychiatric disorders and psychological distress have been
associated with ongoing symptoms and symptom behaviors such as health care seeking,
regardless of the severity of the underlying IBD. We have demonstrated that psychiatric
diagnoses are also associated with inpatient narcotic use in patients with IBD. It is also
likely that more rigorous assessment of psychosocial factors including levels of
psychological distress and coping may provide a greater understanding of psychosocial
contributing factors. Importantly, early recognition and attention to psychosocial difficulties
in patients with IBD may impact a patient’s pain perception and requirement for narcotics.
In these situations early identification may lead to more focused treatment options.
Prior studies have evaluated outpatient chronic narcotic use in patients with IBD. To our
knowledge, quantification of inpatient narcotic use and risk factors in this population has not
been previously described. One of the original descriptions of narcotic use in patients with
IBD was a case series by Kaplan et al describing patients with IBD referred for psychiatric
evaluation. They found relatively high rates of narcotic drug dependence, a majority had CD
and many were diagnosed with borderline personality disorder.25 Edwards et al described a
series of patients with IBD on chronic narcotics without demonstrable organic pathology
and also found a high prevalence of psychiatric disorders in this group (67%).4 Hanson et al
performed a case control study of IBD patients on outpatient narcotics compared to those
without narcotics. They demonstrated that chronic narcotic use in IBD patients is associated
with female gender, >2 previous surgeries, moderate to severe pain, substance abuse,
clinical disease activity, depression, anxiety, and abuse (physical, emotional or sexual).
Importantly, narcotic use was not associated with disease activity when measured by
endoscopic, radiologic or histologic severity.7 Our results in the inpatient setting were
similar to Hanson’s in the outpatient setting. We found that inpatient narcotic use was
significantly associated with prior psychiatric diagnosis, prior IBD surgery and substance
abuse (outpatient narcotic use and smoking). Additional factors in our analysis associated
with inpatient narcotic use included CD, disease duration and IBD-IBS. We, too, found no
association between narcotic use and objective measures of disease activity.
Cross et al found that outpatient narcotic users with IBD were more likely to be female, had
higher rates of disability, took more medications, and had a longer duration of disease.
Similar to a trend in our study, Cross et al found a higher prevalence of neuropsychiatric
drug use among narcotic users. However, they found that CD patients receiving narcotics
had increased levels of disease activity as measured by the Harvey Bradshaw Index (HBI 9.1
vs 5.0, p < 0.001). Several of the components of the HBI are subjective. The HBI is heavily
weighted on general well being and level of abdominal pain.26 These are also symptoms that
would be exacerbated by IBS or visceral hypersensitivity. The lack of association we found
in our study was likely related to our use of objective measures of disease activity:
endoscopic and radiologic findings. Abnormal motility, visceral hypersensitivity, and
psychosocial factors all may play a role in functional gastrointestinal symptoms in patients
with IBD.10 Therefore, the association found by Cross et al could have been as association
between narcotic use and functional GI symptoms.
There are several strengths to our study. First, we were able to capture all inpatient
gastroenterology consultations for a diagnosis of IBD over the one year study period. We
were also able to determine the prevalence of narcotic use with certainty, as information
came directly from billing records. We were able to obtain detailed clinical exposure data
including concurrent medications, disease characteristics and comorbidities. The assessment
of disease severity on endoscopy and CT scan was done independently by 2
gastroenterologists in a blinded fashion, rather than via a subjective disease severity
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measurement. We were also able to describe the hospitalizations of a large number of
consecutive patients with IBD.
There are also several limitations to this study. This represents a single tertiary care center
referral population, which may limit generalizability to other populations. This may
represent a more severe population of patients with IBD, or a more severe population of
patients with coexisting functional GI conditions. Additionally, all data were collected
retrospectively in this cohort, therefore we were limited by medical record documentation.
For example, psychiatric diagnoses were obtained from the medical record, rather than from
formal testing. We also did not have the indication for psychiatric medications, as these
could have been initiated for IBS symptoms and/or depression. For disease severity
measurements, although the endoscopic and radiologic reviewers were blinded to the
patients’ narcotic use, the scoring system remains subjective. The scoring of radiologic tests
was done by gastroenterologists and not radiologists. These limitations could have affected
the lack of association between narcotic use and disease activity. We also could not
completely ascertain doses of narcotics for patients on PCA pumps for pain control. In
general, this subset of patients had the highest narcotic demands, which we were unable to
specifically quantify. However, we could determine with certainty whether narcotics were
received, which is why analyses focused upon any narcotic use. Finally, we were not able to
include pediatric IBD patients in our cohort, as different systems of practice are in place at
our children’s hospital. Little is known about the role of narcotics in children hospitalized
with IBD, and this is an important area for future research.
In summary, the results of our study are important in that we have now shown that a
majority of patients hospitalized for IBD receive narcotics. Narcotics have been associated
with increased complications and also increased mortality in patients with IBD. It has been
previously proposed that narcotics may be a marker for more severe disease, which could
explain these increased risks. In our study, we did not find an association between severe
disease activity and narcotic use, albeit we were limited by sample size. It is also possible
that narcotics themselves precipitate complications such as increased mortality related to
known side effects on the gastrointestinal tract. We were also able to determine risk factors
present at the time of admission that are associated with narcotic use during hospitalization.
Recognition of these risk factors may allow for early interventions during the
hospitalization, such as the addition of centrally acting antidepressants and avoidance of
significant narcotic use, which may ultimately improve pain control and possibly avoid
complications of narcotic use.
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Figure 1. Patients included in Study Population
*For patients with >1 hospitalization, only 1st hospitalization included
**Common variable immunodeficiency
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Table 3
Adjusted Multivariate Analyses of Independent Effects of Risk Factors for Narcotic Use
Characteristic OR* 95% CI**
Gender (Female) 0.77 0.28–2.10
Crohns disease 2.19 0.77–6.22
Current smoking 4.34 1.21–15.6
Psychiatric diagnosis 2.15 0.40–11.6
Duration of IBD (years) 1.04 0.98–1.11
Prior IBD surgery 1.04 0.32–3.42
Outpatient narcotic use 5.41 1.54–19.0
*
Odds Ratio via logistic regression, variables selected a priori from the literature
**
95% CI (Confidence Interval)
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